Related medicinesLeuprolideGoserelinTriptorelinCetrorelixDegarelixRelugolix
Where it comes from
- Made in
- Some ten thousand neurons scattered through the preoptic area, hypothalamus and beyond (the familiar “thousand” is the mouse’s count), which migrated there from the nose before birth
- Sent out by
- In pulses every one to two hours, driven by kisspeptin; the pulse rate sets LH versus FSH
- Acts on
- Pituitary gonadotrophs (LH and FSH)
What it does
- Starts puberty when its pulses resume and keeps cycles and sperm production going
- Continuous exposure desensitises the receptor and switches the axis off, the trick the medicines use 4
- Its neurons’ failure to migrate causes Kallmann syndrome, hypogonadism with no sense of smell
In medicine
- GnRH agonists (leuprolide, goserelin, triptorelin) shut off sex hormones for prostate cancer, endometriosis, fibroids, precocious puberty, IVF and gender-affirming care
- GnRH antagonists do it without the initial surge: cetrorelix and ganirelix in IVF, degarelix and relugolix in prostate cancer, and the tablets elagolix, relugolix and linzagolix for endometriosis and fibroids 2
- Pulsatile gonadorelin by pump restores ovulation and fertility in hypothalamic amenorrhoea and Kallmann syndrome
Beyond the body’s own use
- Agonist and antagonist were compared head to head in 930 men with prostate cancer: oral relugolix held castration in 96.7 per cent against 88.8 per cent for leuprolide, and major cardiovascular events were 2.9 against 6.2 per cent 1
- GnRH and its agonist analogues are banned in sport in male athletes, where a course raises testosterone before it suppresses it; LH and chorionic gonadotropin sit in the same part of the Prohibited List 3
- Long courses lower bone density, which is why add-back oestrogen and progestogen are given alongside the tablets used for endometriosis and fibroids
- Its analogues are not traded outside medicine; they are injections and implants given under specialist care, and the peptide itself is destroyed in the gut
Sources
- Shore et al., Oral relugolix for androgen-deprivation therapy in advanced prostate cancer, New England Journal of Medicine 2020
- Relugolix (Orgovyx), FDA application NDA 214621
- World Anti-Doping Agency, The Prohibited List, section S2
- Millar et al., Gonadotropin-releasing hormone receptors, Endocrine Reviews 2004
This card describes what a medicine is for and what the evidence says; it recommends nothing. Talk to your clinician about anything you read here.